MDM2 SNP309 polymorphism and breast cancer risk: A meta-analysis

Molecular Biology Reports

Volumn 39, Issue 4, 2012, Pages 3471-3477

  Zhao, Erjiang ^a,b   Cui, Dan ^a,b   Yuan, Ling ^b   Lu, Weiquan ^c  

^a ZHENGZHOU UNIVERSITY   (China)

^b Henan Tumor Hospital   (China)

^c Henan Tumor Institute   (China)

Author keywords

Breast cancer; MDM2; Meta analysis; Polymorphism; SNP309

Indexed keywords

PROTEIN MDM2; MDM2 PROTEIN, HUMAN;

ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; ETHNICITY; FAMILY HISTORY; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MOUSE DOUBLE MINUTE 2 GENE; MUTATOR GENE; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; ANIMAL; BREAST TUMOR; CASE CONTROL STUDY; FEMALE; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; MOUSE; PUBLISHING; RISK; RISK FACTOR;

ANIMALS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MICE; ODDS RATIO; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTO-ONCOGENE PROTEINS C-MDM2; PUBLICATION BIAS; RISK FACTORS;

EID: 84863003609     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-011-1119-1     Document Type: Article

References (38)

1. Breast cancer.NHS breast cancer screening programme. http://www. cancerscreening.nhs.uk/breastscreen/breastcancer.html. Accessed 06 May 2009
2. Wolff MS, Weston A (1997) Breast cancer risk and environmental exposures. Environ Health Perspect 105(Suppl 4):891-896
3. Hulka BS, Moorman PG (2001) Breast cancer: Hormones and other risk factors. Maturitas 38:103-113
4. Lundgren K, Montes de Oca Luna R, McNeill YB, Emerick EP, Spencer B, Barfield CR (1997) Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. Genes Dev 11:714-725
5. Alt JR, Bouska A, Fernandez MR, Cerny RL, Xiao H, Eischen CM (2005) Mdm2 binds to Nbs1 at sites of DNA damage and regulates double strand break repair. J Biol Chem 280:18771-18781. doi:10.1074/jbc.M413387200
6. Bond GL, Hu W, Bond EE, Robins H, Lutzker SG, Arva NC et al (2004) A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans. Cell 119:591-602. doi:10.1016/ j.cell.2004.11.022
7. Sdek P, Ying H, Zheng H, Margulis A, Tang X, Tian K et al (2004) The central acidic domain of MDM2 is critical in inhibition of retinoblastoma- mediated suppression of E2F and cell growth. J Biol Chem 279:53317-53322. doi:10.1074/jbc.M406 062200
8. Toi M, Saji S, Suzuki A, Yamamoto Y, Tominaga T (1997) MDM2 in breast cancer. Breast Cancer 4:264-268
9. Rayburn E, Zhang R, He J, Wang H (2005) MDM2 and human malignancies: Expression, clinical pathology, prognostic markers, and implications for chemotherapy. Curr Cancer Drug Targets 5:27-41
10. Chen J, Wu X, Lin J, Levine AJ (1996) mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol 16:2445-2452
11. Akisik E, Yazici H, Dalay N (2010) ARLTS1, MDM2 and RAD51 gene variations are associated with familial breast cancer. Mol Biol Rep 38:343-348. doi:10.1007/s11033-010-0113-3
12. Boersma BJ, Howe TM, Goodman JE, Yfantis HG, Lee DH, Chanock SJ et al (2006) Association of breast cancer outcome with status of p53 and MDM2 SNP309. J Natl Cancer Inst 98:911-919. doi:10.1093/jnci/djj245
13. Campbell IG, Eccles DM, Choong DY (2006) No association of the MDM2 SNP309 polymorphism with risk of breast or ovarian cancer. Cancer Lett 240:195-197. doi:10.1016/j.canlet.2005. 09.003
14. Copson ER, White HE, Blaydes JP, Robinson DO, Johnson PW, Eccles DM (2006) Influence of the MDM2 single nucleotide polymorphism SNP309 on tumour development in BRCA1 mutation carriers. BMC Cancer 6:80. doi:10.1186/1471-2407- 6-80
15. Ma H, Hu Z, Zhai X, Wang S, Wang X, Qin J et al (2006) Polymorphisms in the MDM2 promoter and risk of breast cancer: A case-control analysis in a Chinese population. Cancer Lett 240:261-267. doi:10.1016/j.canlet.2005.09.019
16. Millikan RC, Heard K, Winkel S, Hill EJ, Massa B, Mayes L et al (2006) No association between the MDM2-309 T/G promoter polymorphism and breast cancer in African-Americans or Whites. Cancer Epidemiol Biomarkers Prev 15:175-177. doi: 10.1158/1055-9965.EPI-05-0692
17. Petenkaya A, Bozkurt B, Akilli-Ozturk O, Kaya HS, Gur-Dedeoglu B, Yulug IG (2006) Lack of association between the MDM2-SNP309 polymorphism and breast cancer risk. Anticancer Res 26:4975-4977
18. Wilkening S, Bermejo JL, Burwinkel B, Klaes R, Bartram CR, Meindl A et al (2006) The single nucleotide polymorphism IVS1?309 in mouse double minute 2 does not affect risk of familial breast cancer. Cancer Res 66:646-648. doi:10.1158/ 0008-5472.CAN-05-3168
19. Cox DG, Deer D, Guo Q, Tworoger SS, Hankinson SE, Hunter DJ et al (2007) The p53 Arg72Pro and MDM2-309 polymorphisms and risk of breast cancer in the nurses' health studies. Cancer Causes Control 18:621-625. doi:10.1007/s10552- 007-9004-x
20. Schmidt MK, Reincke S, Broeks A, Braaf LM, Hogervorst FB, Tollenaar RA et al (2007) Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium. Cancer Res 67:9584-9590. doi:10.1158/0008-5472.CAN-07-0738
21. Wasielewski M, Nagel JH, Brekelmans C, Klijn JG, van den Ouweland A, Meijers-Heijboer H et al (2007) MDM2 SNP309 accelerates familial breast carcinogenesis independently of estrogen signaling. Breast Cancer Res Treat 104:153-157. doi: 10.1007/s10549-006-9407-5
22. Krekac D, Brozkova K, Knoflickova D, Hrstka R, Muller P, Nenutil R et al (2008) MDM2SNP309 does not associate with elevated MDM2 protein expression or breast cancer risk. Oncology 74:84-87. doi:10.1159/000139135
23. Lum SS, Chua HW, Li H, Li WF, Rao N, Wei J et al (2008) MDM2 SNP309 G allele increases risk but the T allele is associated with earlier onset age of sporadic breast cancers in the Chinese population. Carcinogenesis 29:754-761. doi:10.1093/ carcin/bgn024
24. Paulin FE, O'Neill M, McGregor G, Cassidy A, Ashfield A, Ali CW et al (2008) MDM2 SNP309 is associated with high grade node positive breast tumours and is in linkage disequilibrium with a novel MDM2 intron 1 polymorphism. BMC Cancer 8:281. doi: 10.1186/1471-2407-8-281
25. Singh V, Rastogi N, Mathur N, Singh K, Singh MP (2008) Association of polymorphism in MDM-2 and p53 genes with breast cancer risk in Indian women. Ann Epidemiol 18:48-57. doi:10.1016/j.annepidem.2007.06.006
26. Yarden RI, Friedman E, Metsuyanim S, Olender T, Ben-Asher E, Papa MZ (2008) MDM2 SNP309 accelerates breast and ovarian carcinogenesis in BRCA1 and BRCA2 carriers of Jewish-Ashkenazi descent. Breast Cancer Res Treat 111:497-504. doi: 10.1007/s10549-007-9797-z
27. Lang A, Palmeback Wegman P, Wingren S (2009) The significance of MDM2 SNP309 and p53 Arg72Pro in young women with breast cancer. Oncol Rep 22:575-579
28. Sinilnikova OM, Antoniou AC, Simard J, Healey S, Leone M, Sinnett D et al (2009) The TP53 Arg72Pro and MDM2 309G[T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Br J Cancer 101:1456-1460. doi:10.1038/sj.bjc.6605279
29. Sun YF, Leu JD, Chen SM, Lin IF, Lee YJ (2009) Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer. BMC Cancer 9:13. doi:10.1186/ 1471-2407-9-13
30. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748
31. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634
32. Freedman DA, Epstein CB, Roth JC, Levine AJ (1997) A genetic approach to mapping the p53 binding site in the MDM2 protein. Mol Med 3:248-259
33. Yu K, Lee CH, Tan PH, Tan P (2004) Conservation of breast cancer molecular subtypes and transcriptional patterns of tumor progression across distinct ethnic populations. Clin Cancer Res 10:5508-5517. doi:10.1158/1078- 0432.CCR-04-0085
34. Lynch HT, Rubinstein WS, Locker GY (2004) Cancer in Jews: Introduction and overview. Fam Cancer 3:177-192. doi: 10.1007/s10689-004-9538-y
35. Easton DF (2002) Familial risks of breast cancer. Breast Cancer Res 4:179-181
36. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P et al (1998) Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 62:676-689
37. Bougeard G, Baert-Desurmont S, Tournier I, Vasseur S, Martin C, Brugieres L et al (2006) Impact of the MDM2 SNP309 and p53 Arg72Pro polymorphism on age of tumour onset in Li-Fraumeni syndrome. J Med Genet 43:531-533. doi:10.1136/jmg. 2005.037952
38. Sotamaa K, Liyanarachchi S, Mecklin JP, Jarvinen H, Aaltonen LA, Peltomaki P et al (2005) p53 codon 72 and MDM2 SNP309 polymorphisms and age of colorectal cancer onset in Lynch syndrome. Clin Cancer Res 11:6840-6844. doi:10.1158/1078-0432.CCR-05-1139